Daily Medication Pearl: Voxelotor (Oxbryta)

Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.

Medication Pearl of the Day: Voxelotor (Oxbryta)

Indication: Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.

Insight:

  • Dosing:Voxelotor can be taken with or without food.Adults and pediatric patients 12 years of age and older: 1500 mg orally once daily
  • Dosage forms: Tablets 500 mg. Tablets for oral suspension 300 mg.
  • Adverse events:Most common adverse reactions (incidence ≥10% with a difference of >3% compared to placebo) are headache, diarrhea, abdominal pain, nausea, rash, and pyrexia.
  • Mechanism of action: Voxelotor binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization. Nonclinical studies suggest that voxelotor may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.
  • Manufacturer: Global Blood Therapeutics

Reference

prescribing-information.pdf (oxbryta.com)